Medical Condition News

RSS

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc. today announced long-term efficacy data from the 12-week double-blind phase and the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with underlying multiple sclerosis or amyotrophic lateral sclerosis.

15 Apr 2010

Infliximab-azathioprine combination helps more Crohn's disease patients achieve remission

A study led by Mayo Clinic suggests remission from Crohn's disease may be more likely if patients get biologic therapy combined with immune-suppressing drugs first instead of immune-suppressing drugs alone. The study, published in the April 15, 2010 issue of the New England Journal of Medicine, found treatment of moderate to severe Crohn's disease with infliximab plus azathioprine allows more patients to achieve remission and mucosal healing than therapy with azathioprine alone.

15 Apr 2010

Successful stem cell therapy performed on CHF patients in Mexico

Bioheart, Inc. announced that treatment with stem cell therapy on two congestive heart failure (CHF) patients was performed successfully at the Hospital Angeles Tijuana, Mexico, through Bioheart's Center of Excellence program with Regenerative Medicine Institute.

15 Apr 2010

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Researchers from the Sackler Center at Weill Cornell Medical College have designed a new class of drugs that targets BCL6, a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma.

15 Apr 2010

Fathers of sexually abused children suffer from anxiety, grief and depression, says study

The preliminary results of a Universit- de Montr-al study show that fathers of sexually abused children can suffer from anxiety, depression and grief. Such patriarchs are often overwhelmed by a desire for vengeance, yet little literature exists to help them deal with their pain.

15 Apr 2010

Research report focuses on key influencers within employer health care market

Health Industries Research Companies' Employer & Coalition Service has released its spring 2010 market research. HIRC finds that employers are increasingly concerned about cancer medications and report sustained interest in health, wellness, and disease management initiatives.

15 Apr 2010

EGEE User Forum to highlight role of grid computing techniques in diagnosing cancer and heart diseases

Cancer, heart and circulatory system diseases cause two thirds of all deaths in Europe. Three research projects at this week's Enabling Grids for E-sciencE (EGEE) User Forum in Uppsala, Sweden, are demonstrating ways that modern computing techniques can investigate today's biggest killers.

15 Apr 2010

FDA: Seven MDIs for treating asthma and COPD to be phased out

The U.S. Food and Drug Administration today announced, in accordance with longstanding U.S. obligations under the Montreal Protocol on Substances that Deplete the Ozone Layer, seven metered-dose inhalers (MDI) used to treat asthma and chronic obstructive pulmonary disease (COPD) will be gradually removed from the U.S. marketplace. These inhalers contain ozone-depleting chlorofluorocarbons (CFCs), which are propellants that move medication out of the inhaler and into the lungs of patients.

15 Apr 2010

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.

15 Apr 2010

Synergistic interactions of A2A Agonist and PDE Inhibitors as adjunctive therapy to GC for treating MM

“Glucocorticoids are a key component of combination therapy regimens in multiple myeloma and other hematological cancers. However, glucocorticoid use comes with substantial dose limiting toxicities. The ability to enhance glucocorticoid dependent effects while sparing associated toxicities may have important implications for the treatment of multiple myeloma and other B-cell malignancies”

15 Apr 2010

Opexa Therapeutics presents key efficacy data on Tovaxin

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the Company presented key efficacy data at the American Academy of Neurology 62nd Annual Meeting held in Toronto, Canada.

15 Apr 2010

ICGC: New era of personalised medicine for cancer patients

Published online today in Nature, a paper authored by over 200 members of the International Cancer Genome Consortium describes the beginnings of a Brave New World, a new era of personalised medicine for cancer patients.

15 Apr 2010

ProCure Proton Therapy Center treats cancer patients with proton therapy technology

The world's first inclined beam treatment room is open and treating patients at the ProCure Proton Therapy Center in Oklahoma City. The third of four treatment rooms at the Oklahoma Center is treating a wide range of tumors with proton therapy, an important alternative to X-ray radiation in treating cancer.

15 Apr 2010

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.

15 Apr 2010

Research team to receive AACR Team Science Award

The fourth annual American Association for Cancer Research Team Science Award will be given to Dana-Farber/Harvard Cancer Center Thoracic Oncology Research Team at the AACR 101st Annual Meeting 2010. This research team is comprised of interdisciplinary investigators from the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center and Harvard Medical School.

15 Apr 2010

New findings may aid in developing medications for atherosclerosis and insulin resistance

Scientists from Eastern Virginia Medical School (EVMS) recently presented preliminary research findings that identify a specific gene as a potential new target for treating obesity-related diseases.

15 Apr 2010

Albert Einstein College of Medicine receives grant to study link between housing status and cardiovascular health

Albert Einstein College of Medicine of Yeshiva University has been awarded $750,000 by the John D. and Catherine T. MacArthur Foundation to study the impact of housing on the cardiovascular health of Latinos in the Bronx.

15 Apr 2010

New UCLA study compares safety and efficacy of angioplasty to bypass surgery

At 56, Tim Obrenski found himself getting so exhausted that he couldn't even pull weeds from his garden. A visit to the cardiologist uncovered a major blockage in his heart's left main artery, and he was told he needed bypass surgery.

15 Apr 2010

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a definitive Clinical Trial Agreement (CTA) with the National Institute on Drug Abuse (NIDA) to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. As part of the CTA, NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the estimated $10 million trial cost.

15 Apr 2010

BIOTRONIK launches new Reocor external pacemakers following European CE Mark approval

BIOTRONIK SE & Co. KG today announced the European launch after receiving CE Mark approval for its new Reocor external pacemakers, available in two models for dual and single chamber pacing therapy.

15 Apr 2010

Medical Condition News

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

Infliximab-azathioprine combination helps more Crohn's disease patients achieve remission

Successful stem cell therapy performed on CHF patients in Mexico

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Fathers of sexually abused children suffer from anxiety, grief and depression, says study

Research report focuses on key influencers within employer health care market

EGEE User Forum to highlight role of grid computing techniques in diagnosing cancer and heart diseases

FDA: Seven MDIs for treating asthma and COPD to be phased out

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Synergistic interactions of A2A Agonist and PDE Inhibitors as adjunctive therapy to GC for treating MM

Opexa Therapeutics presents key efficacy data on Tovaxin

ICGC: New era of personalised medicine for cancer patients

ProCure Proton Therapy Center treats cancer patients with proton therapy technology

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Research team to receive AACR Team Science Award

New findings may aid in developing medications for atherosclerosis and insulin resistance

Albert Einstein College of Medicine receives grant to study link between housing status and cardiovascular health

New UCLA study compares safety and efficacy of angioplasty to bypass surgery

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

BIOTRONIK launches new Reocor external pacemakers following European CE Mark approval

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News